[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Biocells Medical\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":103},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100629173","phase-2-evaluation-of-neuroinduced-mesenchymal-stem-cells-and-mesenchymal-stem-cell-derived-exosomes-in-patients-with-parkinsonism-100629173",false,"NCT07471230","Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism","Phase II Randomized Controlled Trial Evaluating Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism","STEM-PARK","Inclusion Criteria:\n\nAge 40-80 years Clinical diagnosis of Parkinsonism Hoehn and Yahr stage II-III Stable pharmacological treatment for ≥3 months\n\nExclusion Criteria:\n\nAtypical parkinsonian syndromes unrelated to neurodegeneration History of malignancy within 5 years Severe cardiovascular disease Prior cellular therapy Active infection or immunosuppression","ALL","48 Years","70 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This clinical trial investigates the safety and therapeutic potential of mesenchymal stem cell-based therapies in patients with parkinsonism.\n\nThe study evaluates neuroinduced mesenchymal stem cells and mesenchymal stem cell-derived exosomes as potential regenerative treatments targeting neurodegeneration within dopaminergic pathways.",[28,29],"Parkinsonism or Parkinson's Disease Nos","Parkinsonism in Diseases Classified Elsewhere",[31,32,33,34],"mesenchymal","exosomes","parkinsonism","stem cells","NOT_YET_RECRUITING","2026-03-10",{"date":38,"type":39},"2026-03-13","ACTUAL",{"date":41,"type":22},"2026-11-23",{"date":43,"type":22},"2029-11-23",{"name":45,"class":46},"Biocells Medical","INDUSTRY",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":47},"100628711","phase-2-autologous-stem-cell-therapy-in-patients-with-multiple-system-atrophy-100628711","NCT07465198","Autologous Stem Cell Therapy in Patients With Multiple System Atrophy","A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Autologous Stem Cell Therapy in Patients With Multiple System Atrophy","Inclusion Criteria:\n\n* Multiple System Atrophy (MSA-P or MSA-C)\n* Age range of 35 to 65 years\n\nExclusion Criteria:\n\n* Other major neurological disorders\n* Severe cardiac\u002Frenal\u002Fhepatic impairment\n* Prior stem cell therapy","35 Years","65 Years",{"count":58,"type":22},50,[25],"This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. The trial will evaluate functional outcomes, motor performance, and quality of life compared to placebo\u002Fcontrolled group.",[62,63],"MSA - Multiple System Atrophy","MSA",[63,65,66,67],"Multiple System Atrophy","MSC","Mesenchimal stem cells","2026-03-09",{"date":70,"type":39},"2026-03-11",{"date":72,"type":22},"2026-09-01",{"date":74,"type":22},"2031-03-01",{"name":45,"class":46},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":47},"100628906","phase-1-evaluation-of-the-safety-and-preliminary-efficacy-of-neuroinduced-mesenchymal-stem-cells-and-exosome-therapy-in-patients-with-spinocerebellar-palsy-100628906","NCT07467733","Evaluation of the Safety and Preliminary Efficacy of Neuroinduced Mesenchymal Stem Cells and Exosome Therapy in Patients With Spinocerebellar Palsy","Phase I\u002FII Randomized Controlled Study Evaluating the Safety and Preliminary Efficacy of Neuroinduced Mesenchymal Stem Cells and Exosome Therapy in Patients With Spinocerebellar Palsy","NEURO-SCP","Inclusion Criteria:\n\nClinical diagnosis of spinocerebellar palsy confirmed by neurological examination; Disease duration ≤10 years; Ability to provide informed consent.\n\nExclusion Criteria:\n\nSevere systemic illness; Active infection; History of malignancy within 5 years; Prior stem cell therapy; Pregnancy or breastfeeding.","18 Years","45 Years",{"count":87,"type":22},90,[89,25],"PHASE1","This clinical study aims to evaluate the safety and preliminary therapeutic potential of mesenchymal stem cell-derived therapies in patients diagnosed with spinocerebellar palsy. The investigational treatment includes neuroinduced mesenchymal stem cells and their derived exosomes administered via intravenous and intranasal infusion.",[92],"Spinocerebellar Ataxia - All Sub-types",[94,95,32],"ataxia","mesenchymal stem cells",{"date":97,"type":39},"2026-03-12",{"date":99,"type":22},"2026-06-01",{"date":101,"type":22},"2029-06-01",{"name":45,"class":46},""]